Fig. 1From: Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trialsACR responses in patients with early RA a PREMIER and b OPTIMA, or established RA c DE019 and d ARMADA at week 24/26. P value for difference between response rates for patients treated with ADA+MTX and PBO+MTX. ADA, adalimumab; ACR, American College of Rheumatology; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritisBack to article page